Impact of transcatheter aortic valve implantation in patients with reduced ejection fraction by Ayhan, Hüseyin et al.
ORIGINAL ARTICLE
Cardiology Journal 
2015, Vol. 22, No. 1, 108–114
DOI: 10.5603/CJ.a2014.0040
Copyright © 2015 Via Medica
ISSN 1897–5593
108 www.cardiologyjournal.org
Address for correspondence: Hüseyin Ayhan, MD, Ankara Ataturk Education and Research Hospital, Department  
of Cardiology, Street: Bilkent, Postal code: 06800, Ankara, Turkey, tel: +90 3122912525, fax: +90 3122912745,  
e-mail: huseyinayhan44@yahoo.com
Received: 31.03.2014 Accepted: 17.04.2014
Impact of transcatheter aortic valve implantation 
in patients with reduced ejection fraction
Hüseyin Ayhan1, Hacı Ahmet Kasapkara1, Tahir Durmaz1, Telat Keleş1,  
Abdullah Nabi Aslan2, Cenk Sarı2, Serdal Baştuğ2, Emine Bilen2,  
Nihal Akar Bayram1, Murat Akçay1, Engin Bozkurt1
1Department of Cardiology, Faculty of Medicine, Yıldırım Beyazıt University, Turkey 
2Department of Cardiology, Ankara Ataturk Education and Research Hospital, Turkey
Abstract
Background: Aortic stenosis increases with age. According to guidelines, left ventricular sy-
stolic dysfunction is an indication for aortic valve replacement, even in asymptomatic patients. 
There is no clear data on the application of transcatheter aortic valve implantation (TAVI), 
which is a method showing continuous improvement in recent years, in patients with reduced 
ejection fraction (REF) having a poor prognosis for surgical aortic valve replacement. We the-
refore aimed to investigate the effect of TAVI on left ventricular ejection fraction (LVEF) and 
also its efficacy and safety in patients with REF.
Methods and results: The study included 104 patients who underwent transfemoral TAVI 
in our clinic. The patients were divided into two groups: LVEF ≤ 45% (REF group, n = 28) 
and LVEF > 45% (preserved ejection fraction [PEF] group, n = 76). Follow-up measure-
ments were performed at baseline, discharge, 1st, 6th and 12th months. No statistical difference 
was found between the groups with respect to complications and mortality rates. A statistically 
significant difference was detected in LVEF after TAVI, either in all patients (53.9 ± 14.6,  
57.0 ± 11.4, 59.4 ± 8.4, 60.4 ± 6.8, 63.2 ± 3.9, respectively, at baseline, discharge, 1st, 6th and 
12th months, p < 0.001) or in the groups separately. A statistically significant increase in LVEF 
(p < 0.001) was determined at discharge, 1st, 6th and 12th months, whereas LVEF increased in 
all follow-ups of the PEF group, however this elevation reached a statistical significance only 
at the 1st month (p = 0.04).
Conclusions: Our study has shown the positive effect of TAVI on LVEF and its effective and 
safe applicability in patients with REF. (Cardiol J 2015; 22, 1: 108–114)
Key words: transcatheter aortic valve implantation, reduced ejection fraction, 
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Introduction
Severe aortic stenosis (AS) is a common val-
vular heart disease that leads to a high morbidity 
and mortality rate. Aortic valve replacement (AVR) 
is recommended in patients with severe AS that 
are symptomatic or asymptomatic accompanied by 
left ventricular ejection fraction (LVEF) < 50% [1]. 
Surgical replacement of the narrowed aortic valve 
(s-AVR) is performed with a low operative morta-
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lity rate in the absence of severe co-morbid con-
ditions. Patients given s-AVR show both improved 
symptoms and prolonged survival. Nevertheless, 
s-AVR cannot be applied in 30% of patients because 
of left ventricular dysfunction, advanced age, or 
co-morbid conditions [2, 3]. Since s-AVR shows 
a high pre-operative risk, a conservative approach is 
preferred in patients with LVEF (reduced ejection 
fraction [REF]). S-AVR is also associated with 
operative mortality in patients with severe AS and 
REF [4, 5]. Transcatheter aortic valve implantation 
(TAVI) is an effective method for patients with 
severe AS that present a higher surgical risk or 
who cannot undergo s-AVR [6, 7]. Some studies 
have shown an improved effect of TAVI on LVEF 
[8]. However, the efficacy and safety of TAVI in 
patients with REF is not clearly proven. Consequ-
ently, guidelines accept LVEF < 20% as a relative 
contraindication for TAVI [1]. We have also aimed 
in our study to investigate the effect of TAVI on left 
ventricular function in addition to its applicability, 
efficacy, and safety in patients with REF.
Methods
Between July 2011 and July 2013, 104 patients 
who were inoperable or at high risk for s-AVR due 
to severe calcified AS and co-morbid conditions 
were selected for TAVI in our clinic. The patients 
were divided into two groups, the group with pre-
served LVEF (PEF) and the group with reduced 
LVEF (REF). The REF group included a total of 
28 patients. Five patients in the REF group were 
in the low-flow/low-gradient class (mean gradient 
< 40 mm Hg). The diagnosis of severe AS was 
confirmed following dobutamine stress echocar-
diography (DSE) performed with these patients. 
Transthoracic echocardiography (TTE) Doppler 
and 2-dimensional images were obtained from 
parasternal long and short axis, apical 4-chamber, 
and subcostal 4-chamber images. TTE was revie-
wed to assess the pericardium, valvular anatomy 
and function, and cardiac function. All patients 
underwent multi-slice computed tomography 
and transesophageal echocardiography before 
the procedure. Valve morphology, aortic annulus, 
coronary ostium-annulus distance, calcification, 
suitability of peripheral arteries, and the possibi-
lity of an additional pathology were also analyzed. 
Echocardiography (Philips iE33) was performed 
prior to TAVI and at hospital discharge, 1st, 6th and 
12th months follow-ups. Doppler echocardiographic 
measurements included left ventricular end-diasto-
lic volume, where LVEF was calculated with the 
Simpson method, transvalvular pressure gradient 
was determined by the Bernoulli formula, and 
aortic valve area was calculated by the continuity 
equation. All echocardiography parameters were 
evaluated according to guidelines of the American 
Society of Echocardiography [9]. Echocardiography 
evaluations were performed by a single author. 
This is our limitation but intra-observer variability 
was evaluated by performing re-measurements in 
15 patients. Intra-observer variability was found 
to be 5.5% by echocardiographic measurements. 
Because of these patients have frailty we could 
not use the other methods for measurement of 
LVEF like magnetic resonance imaging or nuclear 
scintigraphy.
TAVI was performed through the subclavian 
artery, via a supra-aortic approach and by transfe-
moral access in 5, 1, and 98 patients, respectively. 
TAVI was performed under general anesthesia in 
5 and 12 patients from the REF group and PEF group, 
respectively, while all other patients were given lo-
cal anesthesia. A vascular closure device was used 
in 77 patients while surgical closure was used in 
the remaining patients. Patients were heparinized 
to achieve an activated clotting time of 250–300 s. 
TAVI was performed using Edwards Sapien XT 
(Edwards Lifesciences, Irvine, CA, USA) balloon-
-expandable prostheses. Three valve sizes of 23, 
26, and 29 mm expanded diameter were available. 
As a result, the cardiac surgery team agreed to 
apply TAVI. All patients were informed before 
performing the procedure with the approval of the 
Ethics Committee of our hospital. Stable patients 
were discharged and follow-ups at the 1st, 6th and 
12th months were planned. During the follow-ups, 
routine physical examinations, echocardiography 
and functional capacities were evaluated.
Statistical analysis
All analyses were performed using SPSS 
Statistics Version 17.0. Continuous variables are 
presented as mean and standard deviation and 
were compared by means of a 2-sided Student’s 
t-test. Categorical data are expressed as fre-
quency (percentages) and compared using the 
c2 and Fisher’s exact tests. Echocardiography 
data obtained at baseline, discharge, 1st, 6th and 
12th months were compared by repeated measures 
ANOVA. Continuous variables were compared 
between patients before and after TAVI using the 
paired Student’s t-test (for normally distributed 
variables) or the Wilcoxon test (for non-normally 
distributed variables). Significance was accepted 
as p < 0.05.
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Results
Of the 104 patients, 69 were female and their 
mean age was 78.2 years. Among the patients, 28 
(26.9%) were in the REF group and the rest were in 
the PEF group. The mean valve area was 0.62 cm2 
and the average mean gradient was 52.5 mm Hg 
by echocardiography. Mean and maximal gradients 
were statistically significantly lower in the REF 
group (mean gradient values of REF and PEF 
groups were, respectively, 46.9 ± 13.7 and 54.6 ± 
± 13.2, p = 0.01). Of the patients in the REF group, 
64.2% had LVEF ≤ 35%. Also 4 of these patients 
had LVEF ≤ 20%. Of the patients with LVEF 
≤ 35%, only 5 were in the low-flow/low-gradient 
class. DSE performed in these patients revealed 
contractile reserve.
The mean Society of Thoracic Surgeons (STS) 
score of the patients was 7.4 and the mean logistic 
EUROScore values of the moderate and high risk 
groups were, respectively, 22.7% and 90.3% accor-
ding to the SURTAVI risk model. STS (p < 0.001) 
and logistic EUROScore (p = 0.002) were found 
to be statistically significantly higher in the REF 
group than the PEF group, as expected. Similarly, 
pulmonary artery systolic pressure was statistical-
ly significantly higher (p = 0.04) while LVEF was 
lower (p < 0.001) in the REF group. Although the 
REF group had a severe level of chronic obstructive 
pulmonary disease, no other difference was found 
between the groups with respect to basal charac-
teristics (age, gender, body mass index, New York 
Heart Association [NYHA] functional class, preva-
lence of diabetes or arterial hypertension, history 
of prior myocardial infarction or stroke, previous 
coronary artery bypass grafting, or prevalence of 
atrial fibrillation). The basal characteristics of the 
patients and TAVI data are shown in Table 1.
TAVI could be performed with a 100% proce-
dural success. However, a second valve was used 
in 2 patients due to lower localization in 1 patient 
and valve embolization in the ascending aorta. After 
the procedure, a total of 5 intra-hospital mortalities 
were encountered because of right ventricular 
rupture due to rapid pacing (in 2 patients), left 
ventricular rupture due to wire in the left ventricle, 
postoperative bleeding via supra-aortic approach 
and left main coronary artery obstruction due to 
aortic cusp calcification. All of these 5 intra-hospital 
mortalities were in the PEF group. The follow-ups 
of the patients revealed mortalities in 2, 4 and 
5 patients at respectively the 1st, 6th and 12th months, 
resulting in a total of 16 (15.3%) mortalities. Mor-
tality rates of both groups were similar.
Echocardiographic follow-up was available for 
95% and 85% of patients at discharge and at the 
12th month, respectively. A statistically significant 
improvement was found in valve function (mean 
gradient, aortic valve area) at discharge and at 
follow-up after TAVI. Severe paravalvular aortic 
regurgitation developed in none of the patients 
after TAVI or in follow-ups. Both groups had 
similar rates of >+2 AR detected by TTE (15% 
vs. 24%, p = 0.29). There were no strokes in the 
hospital. Only 4 (3.8%) patients needed permanent 
pacemaker implantation because of atrioventricular 
block. Mean hospital stay was 7.3 ± 5.3 days and 
no difference was found between the groups (8.8 ± 
± 7.1 days in the REF group, 6.8 ± 4.4 days in the 
PEF group; p = 0.09). At the follow-up, 92.8% and 
92.9% of patients in the REF and PEF groups were 
found in class I and class II according to NYHA, re-
spectively. An improvement in functional capacity 
proceeded during the 1st month follow-up (Fig. 1). 
No difference was found between the groups with 
respect to complications.
When the effect of TAVI on left ventricular 
functions was considered, 37 (35.5%) patients and 
28 (26.9%) patients had left ventricular dysfunction 
with LVEF ≤ 50% and LVEF ≤ 45%, respectively. 
No certain definition of patients with REF is pre-
sent in the literature. LVEF can be accepted as 
≤ 50%, ≤ 40%, ≤ 30% and ≤ 45% in identification 
of REF in different studies. We also assigned the 
patients into the REF group according to the most 
commonly used LVEF ≤ 45% value in the literature. 
A statistically significantly increased LVEF was 
found when all patients were evaluated (53.9 ± 
± 14.6, 57.0 ± 11.4, 59.4 ± 8.4, 60.4 ± 6.8, 63.2 ± 
± 3.9 at respectively, baseline, discharge, 1st, 6th, and 
12th month; p < 0.001). When the REF and PEF 
groups were evaluated separately, a statistically 
significantly increased LVEF value (p < 0.001) 
was found at discharge, 1st, 6th, and 12th month in 
the REF group whereas LVEF increased in all 
follow-ups of the PEF group, however this eleva-
tion reached a statistical significance only at the 
1st month (p = 0.04) (Fig. 2). Seventy percent of the 
patients in the REF group reached normal ejection 
fraction (LVEF > 50%) at the 6th month. Ejection 
fraction statistically significantly increased in all of 
the 4 patients with LVEF ≤ 20%, who had increased 
ejection fraction and reached > 45% at the end of 
the 1st month. In the multivariate analyses, there 
was statistically significant negative correlation be-
tween LVEF and STS score, Logistic EUROScore, 
functional capacity (NYHA), mitral regurgitation 
and pulmonary artery systolic pressure. But there 
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Table 1. Basal characteristics and procedural features.
Patient characteristics All patients  
(n = 104)
LVEF ≤ 45%  
(n = 28)
LVEF > 45%  
(n = 76)
P
Male/female 35/69 13/15 22/54 0.10
Age [year] 78.2 ± 7.2 77.4 ± 7.9 78.5 ± 6.9 0.50
Body mass index [kg/m2] 27.9 ± 7.5 28.1 ± 11.6 27.8 ± 5.5 0.89
NYHA class II 7 0 7 0.08
NYHA class III 66 18 48
NYHA class IV 31 10 21
STS 7.4 ± 5.3 11.8 ± 5.3 5.7 ± 4.2 < 0.001
SURTAVI:
Low risk 10 1 9
Moderate risk 34 6 28 0.03
High risk 60 21 39
EUROScore [%] 22.7 ± 15.8 30.2 ± 17.9 19.3 ± 14.1 0.002
Associated comorbid conditions
Coronary artery disease 71.1% 64.2% 73.6% 0.41
Hypertension 81.7% 85.7% 80.2% 0.52
Diabetes mellitus 25.9% 28.5% 25.0% 0.71
Hyperlipidemia 45.2% 42.8% 46.0% 0.77
Smoker 19.2% 25.0% 17.1% 0.36
Chronic obstructive pulmonary disease:
Mild 44.2% 21.4% 52.6%
Moderate 30.7% 28.5% 42.1% < 0.001
Severe 23.0% 50.0% 13.1%
Peripheral arterial disease 34.6% 46.4% 30.2% 0.12
Atrial fibrillation 27.9% 35.7% 25.0% 0.28
Echocardiographic variables
Maximal gradient [mm Hg] 86.2 ± 21.5 76.5 ± 19.2 89.8 ± 21.3 0.005
Mean gradient [mm Hg] 52.5 ± 13.7 46.9 ± 13.7 54.6 ± 13.2 0.01
Aortic valve area [cm2] 0.62 ± 0.17 0.60 ± 0.17 0.63 ± 0.17 0.42
LVEF [%] 53.9 ± 14.5 33.0 ± 10.1 61.5 ± 5.6 < 0.001
Peak SPAP [mm Hg] 47.8 ± 13.6 52.3 ± 15.8 45.9 ± 12.1 0.04
Aortic regurgitation:
Low 17 5 12
Moderate 4 2 2 0.58
Severe 1 0 1
Mitral regurgitation:
Low 62 19 43
Moderate 6 4 2 0.009
Severe 3 1 2
Femoral vascular closure 85.5% 85.7% 85.5% 0.68
Valve diameter [mm]:
23 59 11 48
26 43 15 28 0.01
29 2 2 0
Contrast used [cc] 201.5 ± 55.7 217.4 ± 48.6 195.6 ± 57.3 0.08
Duration of discharge  
after procedure [day]
7.3 ± 5.3 8.8 ± 7.1 6.8 ± 4.4 0.09
NYHA — New York Heart Association, STS — Society of Thoracic Surgeons; SURTAVI — Safety and Efficacy Study of the Medtronic CoreValve® 
System in the Treatment of Severe, Symptomatic Aortic Stenosis in Intermediate Risk Subjects Who Need Aortic Valve Replacement risk model; 
LVEF — left ventricular ejection fraction; SPAP — systolic pulmonary artery pressure
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positive correlation between LVEF and mean gra-
dient of aortic valve.
Discussion
We have shown in our study that TAVI im-
proves left ventricular function in the short and 
moderate periods. We have proven that LVEF, 
functional capacity and clinical results of patients 
with REF improved after TAVI and presented 
a similar prognosis when compared with patients in 
the PEF group. Our results also indicate that TAVI 
may be safe for patients in the REF group; similar 
to patients in the PEF group, and that TAVI may 
be unassociated with an increased per procedural 
risk. It has been shown in the same manner that 
complication rates of patients in the REF group are 
comparable to those in the PEF group. Although 
the incidence of patients with left ventricular 
dysfunction among all patients (35.5% and 26.9% 
according to LVEF ≤ 50% and LVEF ≤ 45%, respec-
tively) was high, similar or better clinical results 
than literature studies have been obtained.
The increased incidence of AS in patients 
brings many co-morbid risk factors with age. One 
of these is left ventricular systolic dysfunction. 
LVEF may decrease due to after load mismatch 
or intrinsic contractile dysfunction [10]. If the 
increased LVEF is not caused by AS, aortic valve 
replacement may provide an improvement in LVEF. 
Aortic valve replacement is recommended for 
patients with REF, whether contractile reserve is 
present or not. DSE was required in only 5 of our 
patients and contractile reserve was sufficient in 
these patients. However, impaired left ventricular 
function is an independent risk factor for early and 
late mortality after s-AVR [11, 12]. Postoperative 
mortalities and complications are also at a high 
incidence even though left ventricular function 
improves after successful s-AVR in patients with 
REF [12, 13]. TAVI has developed rapidly over the 
last decade and has become an important treatment 
option for surgically inoperable or high-risk pa-
tients [6, 7]. Some previous as well as new studies 
indicate improved LVEF after TAVI [8, 14–20]. 
Especially studies conducted in recent years have 
evaluated the effect of TAVI on either LVEF or REF 
in patients. Clavel et al. [8] have compared 200 
patients who underwent s-AVR with 83 patients 
who underwent TAVI for REF (according to LVEF 
≤ 50%) and have shown a better improvement in 
the TAVI group in LVEF than the s-AVR group. 
Bauer et al. [14] found greater improvement at 
the 7th day in 31 patients with REF (according to 
LVEF ≤ 45%) who underwent TAVI compared to 
21 patients receiving s-AVR. They found a simi-
lar improvement with respect to LVEF at the 
3rd month. Pilgrim et al. [16] in their study obtai-
ned results similar to ours, having seen a rapid 
improvement in 30 patients with REF (according 
to LVEF ≤ 30%) after TAVI while no difference was 
found between patients with LVEF > 30% and the 
group with REF with respect to complications and 
mortality. Gotzmann et al. [20] divided patients 
into four groups based on LVEF (LVEF > 50% and 
≤ 50%) and mean gradient (> 40 mm Hg and 
≤ 40 mm Hg ), as group 1, preserved LVEF/high gra-
dient (n = 86), group 2, preserved LVEF/low gra-
Figure 2. Left ventricular ejection fraction (LVEF) on 
baseline, improvement during the in-hospital phase, 
and after a mean follow-up duration of 12 months.
Figure 1. Changes in New York Heart Association (NYHA) 
functional class at 1st month in patients undergoing 
transcatheter aortic valve implantation according to left 
ventricular ejection fraction (LVEF) ≤ 45% or > 45%.
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dient (n = 27), group 3, reduced LVEF/high gradient 
(n = 45), and group 4, reduced LVEF/low gradient 
(n = 44). This study, which used the CoreValve® 
valve, found a statistically significant elevation in 
LVEFs. Nevertheless, this study showed that low 
gradient and/or low LVEF is associated with poor 
clinical results. We accepted LVEF ≤ 45% in our 
study and obtained successful clinical results in the 
patients with either REF or low gradient. Early and 
positive effects of TAVI on LVEF may be explained 
by several mechanisms. TAVI provides a lower 
transprosthetic gradient than s-AVR with its wider 
valve area, thus valve obstruction is completely 
released and pressure load on the left ventricle 
is removed. Improvement of LVEF is lower in 
patients with multivessel coronary artery disease 
who receive s-AVR concurrently with bypass 
whereas revascularization could be performed pre-
viously, when needed, if TAVI is preferred. Beside 
these points, other factors related to open surgery 
during s-AVR, which are irrelevant for TAVI, are 
ischemia, ischemia/reperfusion, inflammatory 
response, cardioplegia, surgical trauma, oxidative 
stress, cardiomyocyte apoptosis due to seve-
ral factors and contractile dysfunction [21]. The 
pure percutaneous approach, local anesthesia and 
non-necessity of vasoactive drug-cardiac arrest-
-prolonged ventilation during TAVI is a protective 
characteristic for the pericardium [16]. Since risk 
scorings (STS, logistic EUROScore) used in patient 
selection and parameters of left ventricular dys-
function were not evaluated sufficiently, it comes 
to the forefront that when we consider these data, 
a scoring system specific for TAVI is necessary. 
TAVI should also be considered instead of s-AVR 
in patients with poor parameters of left ventricular 
function. It is obvious that a value of LVEF ≤ 20% is 
a relative contraindication criteria in the guidelines, 
which should be reevaluated and patient selection 
performed based on additional echocardiography 
criteria (contractile reserve, spackle tracking, left 
ventricular volume and etc.) and clinical criteria 
(fragility, functional capacity, age, gender etc.). It 
can be stated that the procedure can be performed 
with low complication and mortality rates using 
carefully conducted patient selection.
Conclusions
We have shown that an improvement could be 
obtained using TAVI in left ventricular function and 
that TAVI could be performed successfully in the 
REF patient group, producing similar complication 
rates as the PEF patient group. It can be stated 
according to this study that selecting TAVI may 
be necessary instead of s-AVR in patients with left 
ventricular dysfunction and that left ventricular 
functions are important parameters to be taken 
into account in patient selection. Consequently, 
more comprehensive and randomized studies of 
these procedures are necessary.
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